New migraine drug shows promise in Real-World study

NCT ID NCT06409845

Completed Disease control Sponsor: University of Florence Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at how well eptinezumab works and is tolerated for preventing migraines. It included 130 adults with episodic or chronic migraine. Researchers tracked changes in monthly migraine days over 3 to 12 months of treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: eptinezumab
What this could lead to: If successful, this could confirm eptinezumab as an effective preventive treatment for people with frequent migraines.
What could go wrong: This is a completed observational study, not a large randomized trial. Results may not apply to all migraine patients, and individual responses can vary.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC MIGRAINE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Headache Headache Disorders, Secondary migraine disorder migraine with aura migraine without aura Pain

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC MIGRAINE MIGRAINE MIGRAINE WITH AURA MIGRAINE WITHOUT AURA

Contacts and locations

Locations

SISC

Florence, Florence, 50134, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.